相关产品推荐更多 >

Rabbit anti-MMP13 Polyclonal Antibody(Center)【兔抗MMP13多克隆抗体(中心)】
¥1500
Rabbit anti-GLP-1 Polyclonal Antibody【兔抗GLP-1多克隆抗体】
询价
Rabbit anti-ZNF492 Polyclonal Antibody(C-term)【兔抗ZNF492多克隆抗体(C端)】
¥1500
Mouse anti-JMJD6 Monoclonal Antibody(3G5)【鼠抗JMJD6单克隆抗体(3G5)】- abs158090
¥2300
Rabbit anti-CEBPA Polyclonal Antibody【兔抗CEBPA多克隆抗体】- abs151078
¥1600
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 抗体名:
Anti-HEL VHH Mouse IgG2A Fc Isotype Control Monoclonal mAb
- 抗体英文名:
Anti-HEL VHH Mouse IgG2A Fc Isotype Control Monoclonal Antibody
- 靶点:
见优宁维官网
- 浓度:
5-20mg/ml
- 应用范围:
见优宁维官网
- 宿主:
CHO
- 适应物种:
见优宁维官网
- 保质期:
见优宁维官网
- 抗原来源:
见优宁维官网
- 级别:
优级
- 库存:
999
- 供应商:
Absin
- 标记物:
Unlabeled
- 克隆性:
见优宁维官网
- 保存条件:
2 weeks, 2-8℃ under sterile conditions after reconstitution. Avoid repeated freeze-thaw. -80°C for a long-term storage.
- 免疫原:
见优宁维官网
- 规格:
1mg/25mg/5mg
| 规格: | 1mg | 产品价格: | ¥1500.0 |
|---|---|---|---|
| 规格: | 25mg | 产品价格: | ¥17500.0 |
| 规格: | 5mg | 产品价格: | ¥6700.0 |
别名:抗HEL VHH小鼠IgG2A Fc同型对照单克隆抗体
免疫原:见优宁维官网
应用:见优宁维官网
保持条件:2 weeks, 2-8℃ under sterile conditions after reconstitution. Avoid repeated freeze-thaw. -80°C for a long-term storage.
使用方法:Functional/Block/Neutralize
标记:Unlabeled
宿主:CHO
反应种属:见优宁维官网
克隆性:见优宁维官网
产品描述:见优宁维官网
爱必信品牌介绍:

更多详情请了解优宁维网站》》
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Isotype-specific immunostaining with mouse primary antibodies on mouse tissue
) Briefly, substitute your anti H+L pan-reactive secondary antibody with an anti-isotype heavy chain specific secondary. Be aware of possible odd crossreactivties (e.g. many goat anti mouse IgG 1 heavy chain do stain rat IgG 2a
Rapid Isotyping of Mouse Monoclonal Antibodies
, isotyping is useful to control lot to lot consistency, detect contamination by another antibody, and identify hybridoma switch variants (see Notes 2 –8 for further comment on applications). Table 1 Isotype-Dependent Properties of Monoclonal
【翻译】Development trends for monoclonal antibody cancer therapeutics
). However, since 2000, humanized and human mAbs have been entering clinical study at approximately the same rate (4.3 versus 4.5 mAbs per year, respectively). Figure 1 | Categories of monoclonal antibody cancer therapeutics entering clinical study during 1980–1989
技术资料暂无技术资料 索取技术资料





